These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35632561)

  • 1. Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection.
    Handabile C; Sekiya T; Nomura N; Ohno M; Kawakita T; Shingai M; Kida H
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques.
    Chua BY; Sekiya T; Koutsakos M; Nomura N; Rowntree LC; Nguyen THO; McQuilten HA; Ohno M; Ohara Y; Nishimura T; Endo M; Itoh Y; Habel JR; Selva KJ; Wheatley AK; Wines BD; Hogarth PM; Kent SJ; Chung AW; Jackson DC; Brown LE; Shingai M; Kedzierska K; Kida H
    PLoS Pathog; 2022 Oct; 18(10):e1010891. PubMed ID: 36206307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.
    Rosu ME; Kok A; Bestebroer TM; de Meulder D; Verveer EP; Pronk MR; Dekker LJM; Luider TM; Richard M; van den Brand JMA; Fouchier RAM; Herfst S
    J Virol; 2022 Mar; 96(6):e0195921. PubMed ID: 35107371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
    Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
    J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
    Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
    Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
    mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.
    Shingai M; Nomura N; Sekiya T; Ohno M; Fujikura D; Handabile C; Omori R; Ohara Y; Nishimura T; Endo M; Kimachi K; Mitsumata R; Ikeda T; Kitayama H; Hatanaka H; Sobue T; Muro F; Suzuki S; Thanh Nguyen C; Ishigaki H; Nakayama M; Mori Y; Itoh Y; Koutsakos M; Chua BY; Kedzierska K; Brown LE; Jackson DC; Ogasawara K; Kino Y; Kida H
    Vaccine; 2021 Jun; 39(29):3940-3951. PubMed ID: 34090697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.
    Sekiya T; Mifsud EJ; Ohno M; Nomura N; Sasada M; Fujikura D; Daito T; Shingai M; Ohara Y; Nishimura T; Endo M; Mitsumata R; Ikeda T; Hatanaka H; Kitayama H; Motokawa K; Sobue T; Suzuki S; Itoh Y; Brown LE; Ogasawara K; Kino Y; Kida H
    Vaccine; 2019 Apr; 37(15):2158-2166. PubMed ID: 30857932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
    J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot-scale production of inactivated monoglycosylated split H
    Wu CY; Kao SE; Tseng YC; Lin YP; Hou JT; Wu LY; Chiu S; Ma CA; Hsiao PW; Hsiao J; Chen JR
    Antiviral Res; 2023 Aug; 216():105640. PubMed ID: 37263355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
    Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
    mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
    Rockman S; Brown LE; Barr IG; Gilbertson B; Lowther S; Kachurin A; Kachurina O; Klippel J; Bodle J; Pearse M; Middleton D
    J Virol; 2013 Mar; 87(6):3053-61. PubMed ID: 23283953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.